{"transactions":[{"id":833441,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Officer"}}],"security":"Common Stock","published_at":"2026-03-19T21:58:41.000Z","date":"2026-03-18","kind":"sale","planned":false,"acquired":false,"shares":30,"price":32.85,"value":985.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units."}],"balance_after":10276,"source":{"system":"sec-edgar","filing":"0001762572-26-000006","document":"form4-03192026_090337.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000176257226000006/form4-03192026_090337.xml","form_type":"4"}},{"id":833440,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Officer"}}],"security":"Common Stock","published_at":"2026-03-19T21:58:41.000Z","date":"2026-03-18","kind":"sale","planned":false,"acquired":false,"shares":139,"price":31.7888,"value":4418.6432,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive."}],"balance_after":10306,"source":{"system":"sec-edgar","filing":"0001762572-26-000006","document":"form4-03192026_090337.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000176257226000006/form4-03192026_090337.xml","form_type":"4"}},{"id":833439,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Officer"}}],"security":"Common Stock","published_at":"2026-03-19T21:58:41.000Z","date":"2026-03-18","kind":"sale","planned":false,"acquired":false,"shares":1762,"price":31.2838,"value":55122.0556,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive."}],"balance_after":10445,"source":{"system":"sec-edgar","filing":"0001762572-26-000006","document":"form4-03192026_090337.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000176257226000006/form4-03192026_090337.xml","form_type":"4"}},{"id":833438,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Officer"}}],"security":"Common Stock","published_at":"2026-03-19T21:58:41.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":748,"price":33.3754,"value":24964.7992,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive."}],"balance_after":12207,"source":{"system":"sec-edgar","filing":"0001762572-26-000006","document":"form4-03192026_090337.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000176257226000006/form4-03192026_090337.xml","form_type":"4"}},{"id":833437,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Officer"}}],"security":"Common Stock","published_at":"2026-03-19T21:58:41.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":1033,"price":32.7394,"value":33819.8002,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4."}],"balance_after":12955,"source":{"system":"sec-edgar","filing":"0001762572-26-000006","document":"form4-03192026_090337.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000176257226000006/form4-03192026_090337.xml","form_type":"4"}},{"id":837853,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T21:26:50.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date."}],"balance_after":30000,"derivative":{"expiration_date":"2029-03-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001762572-26-000004","document":"form4-03172026_090347.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000176257226000004/form4-03172026_090347.xml","form_type":"4"}},{"id":837852,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Officer"}}],"security":"Common Stock","published_at":"2026-03-17T21:26:50.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported total includes an aggregate 2,186 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d)."}],"balance_after":13988,"source":{"system":"sec-edgar","filing":"0001762572-26-000004","document":"form4-03172026_090347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000176257226000004/form4-03172026_090347.xml","form_type":"4"}},{"id":893324,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-19T21:21:06.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the issuer's common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date."}],"balance_after":48000,"derivative":{"expiration_date":"2030-02-15","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001762572-26-000002","document":"form4-02192026_090202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000176257226000002/form4-02192026_090202.xml","form_type":"4"}},{"id":893323,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Patient Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-19T21:21:06.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date."}],"balance_after":72000,"derivative":{"exercise_price":31.09,"expiration_date":"2036-02-16","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0001762572-26-000002","document":"form4-02192026_090202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000176257226000002/form4-02192026_090202.xml","form_type":"4"}},{"id":1912327,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:00:29.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":8.93,"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-23-013904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013904/ownership.xml","form_type":"4"}},{"id":1912326,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:00:29.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":145000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.39,"underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001493152-23-013904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013904/ownership.xml","form_type":"4"}},{"id":1912325,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:00:29.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":139500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":6.8,"underlying":"Common Stock","underlying_shares":139500},"source":{"system":"sec-edgar","filing":"0001493152-23-013904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013904/ownership.xml","form_type":"4"}},{"id":1912324,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:00:29.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":137750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":12.62,"underlying":"Common Stock","underlying_shares":137750},"source":{"system":"sec-edgar","filing":"0001493152-23-013904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013904/ownership.xml","form_type":"4"}},{"id":1912323,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:00:29.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":14.97,"underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001493152-23-013904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013904/ownership.xml","form_type":"4"}},{"id":2016506,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-02-14T19:16:24.000Z","date":"2023-02-10","kind":"sale","acquired":false,"shares":4500,"price":10.0012,"value":45005.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.02 per share, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001493152-23-005078","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223005078/ownership.xml","form_type":"4"}},{"id":2056519,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-11T21:10:51.000Z","date":"2023-01-10","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 10, 2024) and the remaining 75% will vest and become exercisable monthly over 36 months such that the\noptions are fully vested and exercisable on the four-year anniversary of the grant date (January 10, 2027)."}],"balance_after":200000,"derivative":{"exercise_price":8.93,"expiration_date":"2033-01-10","underlying":"Common Stock, par value $0.0001","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-23-001208","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223001208/ownership.xml","form_type":"4"}},{"id":2091141,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-09T20:31:23.000Z","date":"2022-12-08","kind":"grant","acquired":true,"shares":20663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"As previously reported on a Form 4 filed on July 16, 2020, on July 15, 2020 the Reporting Person was granted a stock option for 137,750 shares of Common Stock, 55,100 of which option shares vest in four equal annual installments commencing on July 15, 2021 and 82,650 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 20,663 of the 82,650 performance option shares on December 8, 2022 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 20,663 option shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Represents the 55,100 time-based option shares referred to in footnote (1) plus the 20,663 vested performance option shares referred to in footnote (4)."}],"balance_after":75763,"derivative":{"exercise_price":12.62,"exercise_date":"2022-12-08","expiration_date":"2030-07-15","underlying":"Common Stock, par value $0.0001","underlying_shares":20663},"source":{"system":"sec-edgar","filing":"0001493152-22-035096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315222035096/ownership.xml","form_type":"4"}},{"id":2091140,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-09T20:31:23.000Z","date":"2022-12-08","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As previously reported on a Form 4 filed on January 8, 2020, on January 7 2020, the Reporting Person was granted a stock option for 400,000 shares of Common Stock, 160,000 of which option shares vest in four equal annual installments commencing on January 7, 2021 and 240,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 120,000 of the 240,000 performance option shares on December 8, 2022 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 120,000 option shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents the 160,000 time-based option shares referred to in footnote (1) plus the 120,000 vested performance option shares referred to in footnote (1) plus 60,000 vested performance shares which vested on September 2, 2020."}],"balance_after":340000,"derivative":{"exercise_price":14.97,"exercise_date":"2022-12-08","expiration_date":"2030-01-07","underlying":"Common Stock, par value $0.0001","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001493152-22-035096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315222035096/ownership.xml","form_type":"4"}},{"id":2430627,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-20T17:20:09.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 18, 2023) and the remaining 75% will vest and become exercisable monthly over 36 months such that the\noptions are fully vested and exercisable on the four-year anniversary of the grant date (January 18, 2026)."}],"balance_after":145000,"derivative":{"exercise_price":4.39,"expiration_date":"2032-01-18","underlying":"Common Stock, par value $0.0001","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001493152-22-001752","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315222001752/ownership.xml","form_type":"4"}},{"id":2712402,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-05-14T19:39:30.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":139500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"69,750 of the options granted will vest as follows: 25% will vest and become exercisable on May 12, 2022 and 75% will vest and become exercisable monthly over 36 months such that these options will be fully vested and exercisable on May 12, 2025. The remaining 69,750 of the options granted will vest and become exercisable, if at all, in three equal installments of 23,250 options, with each such installment triggered upon the achievement of one of three separate corporate performance milestones prior to or during the year 2024."}],"balance_after":139500,"derivative":{"exercise_price":6.8,"expiration_date":"2031-05-12","underlying":"Common Stock, par value $0.0001","underlying_shares":139500},"source":{"system":"sec-edgar","filing":"0001493152-21-011579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315221011579/ownership.xml","form_type":"4"}},{"id":3081849,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option (right to buy)","published_at":"2020-07-16T18:01:10.000Z","date":"2020-07-15","kind":"grant","acquired":true,"shares":137750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"55,100 option shares vest in four equal annual installments commencing on July 15, 2021; the remaining 82,650 options shares vest upon completion of certain performance milestones. The completion of each milestone vests 15% of the total option shares."}],"balance_after":137750,"derivative":{"exercise_price":12.62,"expiration_date":"2030-07-15","underlying":"Common Stock, par value $0.0001","underlying_shares":137750},"source":{"system":"sec-edgar","filing":"0001493152-20-013476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315220013476/ownership.xml","form_type":"4"}},{"id":3199397,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-20T06:15:21.000Z","date":"2020-03-19","kind":"purchase","acquired":true,"shares":4500,"price":5.43,"value":24435.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.45, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":4500,"source":{"system":"sec-edgar","filing":"0001493152-20-004385","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315220004385/ownership.xml","form_type":"4"}},{"id":3315303,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option (right to buy)","published_at":"2020-01-08T17:00:12.000Z","date":"2020-01-07","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 7, 2020, pursuant to the Issuer's 2017 Equity Incentive Plan. 160,000 option shares vest in four equal annual installments commencing on January 7, 2021; the remaining 240,000 option shares vest upon completion of certain performance milestones."}],"balance_after":400000,"derivative":{"exercise_price":14.97,"expiration_date":"2030-01-07","underlying":"Common Stock, par value $0.0001","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001493152-20-000369","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315220000369/ownership.xml","form_type":"4"}},{"id":3374594,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-11-12T16:35:38.000Z","date":"2019-11-12","kind":"disposition_to_issuer","acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $5,357,500.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $5,357,500.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option."}],"balance_after":0,"derivative":{"exercise_price":6.07,"expiration_date":"2028-12-18","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-19-056030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919119056030/doc4.xml","form_type":"4"}},{"id":3374593,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-11-12T16:35:38.000Z","date":"2019-11-12","kind":"disposition_to_issuer","acquired":false,"shares":9970,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the \"Merger\") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which  represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the \"Merger\") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which  represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-056030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919119056030/doc4.xml","form_type":"4"}},{"id":3401159,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-10-02T16:20:51.000Z","date":"2019-09-30","kind":"sale","acquired":false,"shares":2387,"price":28,"value":66836.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units."}],"balance_after":9970,"source":{"system":"sec-edgar","filing":"0001562180-19-005056","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000156218019005056/primarydocument.xml","form_type":"4"}},{"id":3460834,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-07-16T16:29:33.000Z","date":"2019-07-15","kind":"sale","acquired":false,"shares":900,"price":16.44,"value":14796.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.07 to $16.99 inclusive."}],"balance_after":12357,"source":{"system":"sec-edgar","filing":"0001209191-19-042168","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919119042168/doc4.xml","form_type":"4"}},{"id":3460833,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-07-16T16:29:33.000Z","date":"2019-07-15","kind":"sale","acquired":false,"shares":6680,"price":15.1,"value":100868.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":13257,"source":{"system":"sec-edgar","filing":"0001209191-19-042168","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919119042168/doc4.xml","form_type":"4"}},{"id":3471390,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-07-02T16:55:55.000Z","date":"2019-06-28","kind":"sale","acquired":false,"shares":150,"price":14.4,"value":2160.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.38 to $14.43 inclusive."}],"balance_after":19937,"source":{"system":"sec-edgar","filing":"0001209191-19-040366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919119040366/doc4.xml","form_type":"4"}},{"id":3471389,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-07-02T16:55:55.000Z","date":"2019-06-28","kind":"sale","acquired":false,"shares":2237,"price":13.77,"value":30803.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.35 to $14.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":20087,"source":{"system":"sec-edgar","filing":"0001209191-19-040366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919119040366/doc4.xml","form_type":"4"}},{"id":3558587,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-04-10T16:48:29.000Z","date":"2019-04-08","kind":"sale","acquired":false,"shares":2387,"price":8.77,"value":20933.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.62 to $8.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":22324,"source":{"system":"sec-edgar","filing":"0001209191-19-024262","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919119024262/doc4.xml","form_type":"4"}},{"id":3723416,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-12-20T17:27:17.000Z","date":"2018-12-19","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service with the Issuer as of each such date."}],"balance_after":250000,"derivative":{"exercise_price":6.07,"expiration_date":"2028-12-18","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-18-063713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919118063713/doc4.xml","form_type":"4"}},{"id":3723415,"issuer":{"id":153784,"kind":"organization","name":"Dova Pharmaceuticals Inc.","symbol":"DOVA"},"owners":[{"id":57124,"kind":"person","name":"Hoitt Jason","position":1,"cik":"0001762572","reported_name":"Hoitt Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-12-20T17:27:17.000Z","date":"2018-12-19","kind":"grant","acquired":true,"shares":24711,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests 25% on each of March 29, 2019, June 28, 2019, September 30, 2019 and December 31, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Issuer common stock."}],"balance_after":24711,"source":{"system":"sec-edgar","filing":"0001209191-18-063713","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685071/000120919118063713/doc4.xml","form_type":"4"}}]}